Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETITE-DTG: Dolutegravir PK in HIV-exposed Neonates
NCT05590325Phase 2Unknown
- Sponsor
- Desmond Tutu TB Centre
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by Desmond Tutu TB Centre. Status: unknown.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05590325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05590325.